What have we learned from the novel human cytochromes P450 hidden in the databases?

Current Genomics

Volumn 7, Issue 5, 2006, Pages 273-282

  Cauffiez, Christelle ^a  

^a IMPECS IMPact de l Environnement Chimique sur la Santé humaine   (France)

Author keywords

Cytochromes P450; Human Genome Project; Pharmacogenetics; Xenobiotics

Indexed keywords

CHLORZOXAZONE; COLECALCIFEROL; CYTOCHROME P450; CYTOCHROME P450 2A; CYTOCHROME P450 4A; ICOSANOID; PROSTANOID; SKATOLE; STEROID; XENOBIOTIC AGENT;

AUTOSOMAL RECESSIVE DISORDER; CANCER RISK; CARCINOGENESIS; CLINICAL FEATURE; COMPUTER MODEL; COMPUTER SIMULATION; DISEASE PREDISPOSITION; EMBRYO DEVELOPMENT; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME METABOLISM; FATTY ACID METABOLISM; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE FUNCTION; GENE IDENTIFICATION; GENE LOCATION; GENE MUTATION; GENE OVEREXPRESSION; GENETIC ASSOCIATION; GENETIC CODE; GENETIC DATABASE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; INTERNET; LUNG CANCER; LUNG CARCINOGENESIS; MEDICAL INFORMATION; MUTATIONAL ANALYSIS; PROTEIN DATABASE; PSEUDOGENE; RETINA DYSTROPHY; REVIEW; RISK ASSESSMENT; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; VITAMIN D DEFICIENCY;

EID: 33749995842     PISSN: 13892029     EISSN: None     Source Type: Journal    
DOI: 10.2174/138920206778604359     Document Type: Review

References (104)

1. Nelson, D.R. Cytochrome P450 nomenclature, 2004. Methods Mol. Biol. 2006, 320: 1-10.
2. Parkinson, A. Casarett and Doull's toxicology: the basis science of poisons. Klaassen CD Editor. McGraw Hill Companies, 1996, 113-186
3. Rendic, S. Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab. Rev. 2002, 34: 83-448.
4. Ding, X., Kaminsky, L.S. Human extrahepatic cytochromes P450: function in xenobiotic metabolism and tissue-selective chemical toxicity in the respiratory and gastrointestinal tracts. Annu. Rev. Pharmacol. Toxicol. 2003, 43: 149-73
5. Danielson, P.B. The cytochrome P450 superfamily: biochemistry, evolution and drug metabolism in humans. Curr. Drug. Metab. 2002, 3: 561-597.
6. Klingenberg, M. Pigments of rat liver microsomes. Arch. Biochem. Biophys. 1958, 75: 376-386.
7. Omura, T., Sato, R. A new cytochrome in liver microsomes. J. Biol. Chem. 1962, 237: 1375-1376.
8. Omura, T., Sato, R., Cooper, D.Y., Rosenthal, O., Estabrook, R.W. Function of cytochrome P-450 of microsomes. Fed. Proc. 1965, 24: 1181-1189.
9. Cooper, D.Y., Schleyer, H., Rosenthal, O. Some chemical properties of cytochrome P-450 and its carbon monoxide compound (P-450.CO). Ann. NY. Acad. Sci. 1970, 174: 205-217.
10. Ryan, D., Lu., Kawalek, J., West, S.B., Levin, L. Highly purified cytochrome P-448 and P-450 from rat liver microsomes. Biochem. Biophys. Res. Commun. 1975, 64: 1134-1141.
11. Weissenbach, J. Le génome humain: des promesses aux réalités. Bulletin de l'ordre, 2003, 381: 375-387.
12. Nelson, D.R. 'Frankenstein genes', or the Mad Magazine version of the human pseudogenome. Hum. Genomics. 2004, 1: 310-316.
13. Nelson, D.R. Comparison of P450s from human and fugu: 420 million years of vertebrate P450 evolution. Arch. Biochem. Biophys. 2003, 409: 18-24.
14. Ingelman-Sundberg, M. Genetic susceptibility to adverse effects of drugs and environmental toxicants. The role of the CYP family of enzymes. Mutat. Res. 2001, 482: 11-19.
15. Ingelman-Sundberg, M. The human genome project and novel aspects of cytochromes P450 research. Toxicol. Appl. Pharmacol. 2005, 207: 52-56.
16. Guengerich, F.P., Wu, Z.L., Bartleson, C.J. Function of human cytochrome P450s: characterization of the orphans. Biochem. Biophys. Res. Commun. 2005, 338: 465-469.
17. Nebert, D.W., Russell, D.W. Clinical importance of the cytochromes P450. Lancet 2002, 360: 1155-1162.
18. Forest, M.G., Tardy, V., Nicolino, M., David, M., Morel, Y. 21-Hydroxylase deficiency: an exemplary model of the contribution of molecular biology in the understanding and management of the disease. Ann. Endocrinol. 2005, 66: 225-232.
19. Fujieda, K., Tajima, T. Molecular basis of adrenal insufficiency. Pediatr. Res. 2005, 57: 62R-69R.
20. Ho, C.L., Walton, D.S. Primary congenital glaucoma: 2004 update. J Pediatr. Ophthalmol. Strabismus. 2004, 41: 271-288.
21. Wang, J., Freeman, D. J., Grundy, S.M., Levine, D.M., Guerra, R., Cohen, J.C. Linkage between cholesterol 7-alpha-hydroxylase and high plasma low-density lipoprotein cholesterol concentrations. J. Clin. Invest. 1998, 101: 1283-1291.
22. Setchell, K.D.R., Schwarz, M., O'Connell, N.C., Lund, E.G., Davis, D.L., Lathe, R., Thompson, H.R., Tyson, R.W., Sokol, R.J., Russell, D.W. Identification of a new inborn error in bile acid synthesis: mutation of the oxysterol 7-alpha-hydroxylase gene causes severe neonatal liver disease. J. Clin. Invest. 1998, 102: 1690-1703.
23. Cheng, J.B., Motola, D.L., Mangelsdorf, D.J., Russell, D.W. Deorphanization of cytochrome P450 2R1: a microsomal vitamin D 25-hydroxilase. J. Biol. Chem. 2003, 278: 38084-38093.
24. Shinkyo, R., Sakaki, T., Kamakura, M., Ohta, M., Inouye, K. Metabolism of vitamin D by human microsomal CYP2R1. Biochem. Biophys. Res. Commun. 2004, 324: 451-457.
25. Prosser, D.E., Jones, G. Enzymes involved in the activation and inactivation of vitamin D. Trends Biochem. Sci. 2004, 29: 664-673.
26. Casella, S. J., Reiner, B. J., Chen, T. C., Holick, M. F., Harrison, H. E. A possible genetic defect in 25-hydroxylation as a cause of rickets. J. Pediat. 1994, 124: 929-932.
27. Cheng. J.B., Levine, M.A., Bell, N.H., Mangelsdorf, D.J., Russell, D.W. Genetic evidence that the human CYP2R1 enzyme is a key vitamin D 25-hydroxylase. Proc. Natl. Acad. Sci. USA 2004, 101: 7711-7715.
28. Thacher, T.D., Fischer, P.R., Pettifor, J.M., Lawson, J.O., Isichei, C.O., Chan, G.M. Case-control study of factors associated with nutritional rickets in Nigerian children. J. Pediat. 2000, 137: 367-373.
29. Williams, M.L., Elias, P.M. Heterogeneity in autosomal recessive ichthyosis. Clinical and biochemical differentiation of lamellar ichthyosis and nonbullous congenital ichthyosiform erythroderma. Arch. Dermatol. 1985, 121: 477-488.
30. Richard, G. Molecular genetics of the ichthyoses. Am. J. Med. Genet. C. Semin. Med. Genet. 2004, 131: 32-44.
31. Lefevre, C., Bouadjar, B., Ferrand, V., Tadini, G., Megarbane, A., Lathrop, M., Prud'homme, J.F., Fischer, J. Mutations in a new cytochrome P450 gene in lamellar ichthyosis type 3. Hum. Mol. Genet. 2006, 15: 767-776.
32. Segre, J.A. Epidermal barrier formation and recovery in skin disorders. J. Clin. Invest. 2006, 116: 1150-1158.
33. Hu, D.N. Ophthalmic genetics in China. Ophthal. Paediat. Genet. 983, 2: 39-45.
34. Li, A., Jiao, X., Munier, F.L., Schorderet, D.F., Yao, W., Iwata, F., Hayakawa, M., Kanai, A., Shy Chen, M., Alan Lewis, R., Heckenlively, J., Weleber, R.G., Traboulsi, E.I., Zhang, Q., Xiao, X., Kaiser-Kupfer, M., Sergeev, Y.V., Hejtmancik, J.F. Bietti crystalline corneoretinal dystrophy is caused by mutations in the novel gene CYP4V2. Am. J. Hum. Genet. 2004, 74: 817-826.
35. Lin, J., Nishiguchi, K.M., Nakamura, M., Dryja, T.P., Berson, E.L., Miyake, Y. Recessive mutations in the CYP4V2 gene in East Asian and Middle Eastern patients with Bietti crystalline corneoretinal dystrophy. J. Med. Genet. 2005, 42: e38.
36. Wada, Y., Itabashi, T., Sato, H., Kawamura, M., Tada, A., Tamai, M. Screening for mutations in CYP4V2 gene in Japanese patients with Bietti's crystalline corneoretinal dystrophy. Am. J. Ophthalmol. 2005, 139: 894-899.
37. Shan, M., Dong, B., Zhao, X., Wang, J., Li, G., Yang, Y., Li, Y. Novel mutations in the CYP4V2 gene associated with Bietti crystalline corneoretinal dystrophy. Mol. Vis. 2005, 11: 738-743.
38. Lee, K.Y., Koh, A.H., Aung, T., Yong, V.H., Yeung, K., Ang, C.L., Vithana, E.N. Characterization of Bietti crystalline dystrophy patients with CYP4V2 mutations. Invest. Ophthalmol. Vis. Sci. 2005, 46: 3812-3816.
39. Gekka, T., Hayashi, T., Takeuchi, T., Goto-Omoto, S., Kitahara, K. CYP4V2 mutations in two Japanese patients with Bietti's crystalline dystrophy. Ophthalmic. Res. 2005, 37: 262-269.
40. Honkakoski, P., Negishi, M. The structure, function, and regulation of cytochrome P450 2A enzymes. Drug. Metab. Rev. 1997, 29: 977-996.
41. Su, T., Bao, Z., Zhang, Q.Y., Smith, T.J., Hong, J.Y., Ding, X. Human cytochrome P450 CYP2A13: predominant expression in the respiratory tract and its high efficiency metabolic activation of a tobacco-specific carcinogen, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. Cancer Res. 2000, 60: 5074-5079.
42. He, X.Y., Tang, L., Wang, S.L., Cai, Q.S., Wang, J.S., Hong, J.Y. Efficient activation of aflatoxin B1 by cytochrome P450 2A13, an enzyme predominantly expressed in human respiratory tract. Int. J. Cancer 2006, 118: 2665-2671.
43. Bao, Z., He, X.Y., Ding, X., Prabhu, S., Hong, J.Y. Metabolism of nicotine and cotinine by human cytochrome P450 2A13. Drug. Metab. Dispos. 2005, 33: 258-261.
44. Gu, J., Su, T., Chen, Y., Zhang, Q.Y., Ding, X. Expression of biotransformation enzymes in human fetal olfactory mucosa: potential roles in developmental toxicity. Toxicol. Appl. Pharmacol. 2000, 165: 158-162.
45. Chen, Y., Liu, Y.Q., Su, T., Ren, X., Shi, L., Liu, D., Gu, J., Zhang, Q.Y., Ding, X. Immunoblot analysis and immunohistochemical characterization of CYP2A expression in human olfactory mucosa. Biochem Pharmacol. 2003, 66: 1245-1251.
46. Zhang, X., Su, T., Zhang, Q.Y., Gu, J., Caggana, M., Li, H., Ding, X. Genetic polymorphisms of the human CYP2A13 gene: identification of single-nucleotide polymorphisms and functional characterization of an Arg257Cys variant. J. Pharmacol. Exp. Ther. 2002, 302: 416-423.
47. Wang, H., Tan, W., Hao, B., Miao, X., Zhou, G., He, F., Lin, D. Substantial reduction in risk of lung adenocarcinoma associated with genetic polymorphism in CYP2A13, the most active cytochrome P450 for the metabolic activation of tobacco-specific carcinogen NNK. Cancer Res. 2003, 63: 8057-8061.
48. Zhang, X., Caggana, M., Cutler, T.L., Ding, X. Development of a real-time polymerase chain reaction-based method for the measurement of relative allelic expression and identification of CYP2A13 alleles with decreased expression in human lung. J. Pharmacol. Exp. Ther. 2004, 311: 373-381.
49. Day, D.A., Tuite, M.F. Post-transcriptional gene regulatory mechanisms in eukaryotes: an overview. J. Endocrinol. 1998, 157: 361-71
50. Cauffiez. C., Lo-Guidice, J.M., Quaranta, S., Allorge, D., Chevalier, D., Cenee, S., Hamdan, R., Lhermitte, M., Lafitte, J.J., Libersa, C., Colombel, J.F., Stucker, I., Broly, F. Genetic polymorphism of the human cytochrome CYP2A13 in a French population: implication in lung cancer susceptibility. Biochem. Biophys. Res. Commun. 2004, 317: 662-669.
51. Zhang, X., Chen, Y., Liu, Y., Ren, X., Zhang, Q.Y., Caggana, M., Ding, X. Single nucleotide polymorphisms of the human cyp2a13 gene: evidence for a null allele. Drug Metab. Dispos. 2003, 31: 1081-1085.
52. Jiang, J.H., Jia, W.H., Chen, H.K., Feng, B.J., Qin, H.D., Pan, Z.G., Shen, G.P., Huang, L.X., Feng, Q.S., Chen, L.Z., Lin, D.X., Zeng, Y.X. Genetic polymorphisms of CYP2A13 and its relationship to nasopharyngeal carcinoma in the Cantonese population. J. Transl. Med. 2004, 2: 24.
53. Cauffiez. C., Pottier, N., Tournel, G., Lo-Guidice, J.M., Allorge, D., Chevalier, D., Migot-Nabias, F., Kenani, A., Broly, F. CYP2A13 genetic polymorphism in French Caucasian, Gabonese and Tunisian populations. Xenobiotica 2005, 35: 661-669.
54. von Weymarn, L.B., Zhang, Q.Y., Ding, X., Hollenberg, P.F., Effects of 8-methoxypsoralen on cytochrome P450 2A13. Carcinogenesis 2005, 26: 621-629.
55. Rylander, T., Neve, E.P., Ingelman-Sundberg, M., Oscarson, M. Identification and tissue distribution of the novel human cytochrome P450 2S1 (CYP2S1). Biochem. Biophys. Res. Commun. 2001, 281: 529-535.
56. Smith, G., Wolf, C.R., Deeni, Y.Y., Dawe, R.S., Evans, A.T., Comrie, M.M., Ferguson, J., Ibbotson, S.H. Cutaneous expression of cytochrome P450 CYP2S1: individuality in regulation by therapeutic agents for psoriasis and other skin diseases. Lancet 2003, 361: 1336-1343.
57. Saarikoski, S.T., Wikman, H.A., Smith, G., Wolff, C.H., Husgafvel-Pursiainen, K. Localization of cytochrome P450 CYP2S1 expression in human tissues by in situ hybridization and immunohistochemistry. J. Histochem. Cytochem. 2005, 53: 549-556.
58. Saarikoski, S.T., Rivera, S.P., Hankinson, O., Husgafvel-Pursiainen, K. CYP2S1: A short review. Toxicol. Appl. Pharmacol. 2005, 207: 62-69.
59. Karlgren, M., Miura, S., Ingelman-Sundberg, M. Novel extrahepatic cytochrome P450s. Toxicol. Appl. Pharmacol. 2005, 207: 57-61.
60. Rivera, S.P., Saarikoski, S.T., Hankinson, O. Identification of a novel dioxin-inducible cytochrome P450. Mol. Pharmacol. 2002, 61: 255-259.
61. Stoilov, I. Cytochrome P450s: coupling development and environment. Trends Genet. 2001, 17: 629-632.
62. Choudhary, D., Jansson, I., Schenkman, J.B., Sarfarazi, M., Stoilov, I. Comparative expression profiling of 40 mouse cytochrome P450 genes in embryonic and adult tissues. Arch. Biochem. Biophys. 2003, 414: 91-100.
63. Saarikoski, S.T., Suitiala, T., Holmila, R., Impivaara, O., Jarvisalo, J., Hirvonen, A., Husgafvel-Pursiainen, K. Identification of genetic polymorphisms of CYP2S1 in a Finnish Caucasian population. Mutat. Res. 2004, 554: 267-277.
64. Chuang, S.S., Helvig, C, Taimi, M., Ramshaw, H.A., Collop, A.H., Amad, M., White, J.A., Petkovich, M., Jones, G., Korczak, B. CYP2U1, a novel human thymus- and brain-specific cytochrome P450, catalyzes omega- and (omega-1)-hydroxylation of fatty acids. J. Biol. Chem. 2004, 279: 6305-6314.
65. Karlgren, M., Backlund, M., Johansson, I., Oscarson, M., Ingelman-Sundberg, M. Characterization and tissue distribution of a novel human cytochrome P450-CYP2U1. Biochem. Biophys. Res. Commun. 2004, 315: 679-685.
66. Escalante, B., Sessa, W.C., Falck, J.R., Yadagiri, P., Schwartzman, M.L. Cytochrome P450-dependent arachidonic acid metabolites, 19- and 20-hydroxyeicosatetraenoic acids, enhance sodium-potassium ATPase activity in vascular smooth muscle. J Cardiovasc. Pharmacol. 1990, 16: 438-443.
67. Miyata, N., Roman R.J. Role of 20-hydroxyeicosatetraenoïc acid (20-HETE) in vascular system. J. Smooth Muscle Res. 2005, 41: 175-193.
68. Yoshioka, H., Kasai, N., Ikushiro, S., Shinkyo, R., Kamakura, M., Ohta, M., Inouye, K., Sakaki; T. Enzymatic properties of human CYP2W1 expressed in Escherichia coli. Biochem. Biophys. Res. Commun. 2006, 345: 169-174.
69. Du, L., Neis, M.M., Ladd, P.A., Lanza, D.L., Yost, G.S., Keeney, D.S. Effects of the differentiated keratinocyte phenotype on expression levels of CYP1-4 family genes in human skin cells. Toxicol. Appl. Pharmacol. 2006, 213: 135-144.
70. Karlgren, M., Gomez, A., Stark, K., Svard, J., Rodriguez-Antona, C., Oliw, E., Bernal, M.L., Ramon y Cajal, S., Johansson, J., Ingelman-Sundberg, M. Tumor-specific expression of the novel cytochrome P450 enzyme, CYP2W1. Biochem. Biophys. Res. Commun. 2006, 341: 451-458.
71. Bylund. J., Bylund. M., Oliw, E.H. cDna cloning and expression of CYP4F12, a novel human cytochrome P450. Biochem. Biophys. Res. Commun. 2001, 280: 892-897.
72. Hashizume, T., Imaoka, S., Hiroi, T., Terauchi, Y., Fujii, T., Miyazaki, H., Kamataki, T., Funae, Y. cDNA cloning and expression of a novel cytochrome p450 (cyp4f12) from human small intestine. Biochem. Biophys. Res. Commun. 2001, 280: 1135-1141.
73. Hashizume, T., Imaoka, S., Mise, M., Terauchi, Y., Fujii, T., Miyazaki, H., Kamataki, T., Funae, Y. Involvement of CYP2J2 and CYP4F12 in the metabolism of ebastine in human intestinal microsomes. J. Pharmacol. Exp. Ther. 2002, 300: 298-304.
74. Stark, K., Schauer, L., Sahlen, G.E., Ronquist, G., Oliw, E.H. Expression of CYP4F12 in gastrointestinal and urogenital epithelia. Basic Clin. Pharmacol. Toxicol. 2004, 94: 177-183.
75. Cauffiez, C., Klinzig, F., Rat, E., Tournel, G., Allorge, D., Chevalier, D., Lovecchio, T., Pottier, N., Colombel, J.F., Lhermitte, M., D'Halluin, J.C., Broly, F., Lo-Guidice, J.M. Functional characterization of genetic polymorphisms identified in the human cytochrome P450 4F12 (CYP4F12) promoter region. Biochem. Pharmacol. 2004, 67: 2231-2238.
76. Cauffiez, C., Klinzig, F., Rat, E., Tournel, G., Allorge, D., Chevalier, D., Pottier, N., Lovecchio, T., Colombel, J.F., Lhermitte, M., Lo-Guidice, J.M., Broly, F. Human CYP4F12 genetic polymorphism: identification and functional characterization of seven variant allozymes. Biochem; Pharmacol. 2004, 68: 2417-2425.
77. Savas, U., Hsu, M.H., Griffin, K.J., Bell, D.R., Johnson, E.F. Conditional regulation of the human CYP4X1 and CYP4Z1 genes. Arch. Biochem. Biophys. 2005, 436: 377-385.
78. Al-Anizy, M., Horley, N.J., Kuo, C.W., Gillett, L.C., Laughton, C.A., Kendall, D., Barrett, D.A., Parker, T., Bell, D.R. Cytochrome P450 Cyp4x1 is a major P450 protein in mouse brain. FEBS J. 2006, 273: 936-947.
79. Rieger, M.A., Ebner, R., Bell, D.R., Kiessling, A., Rohayem, J., Schmitz, M., Temme, A., Rieber, E.P., Weigle, B. Identification of a novel mammary-restricted cytochrome P450, CYP4Z1, with overexpression in breast carcinoma. Cancer Res. 2004, 64: 2357-2364.
80. Gonzalez, F., Kimura, S. Study of P450 function using gene knockout and transgenic mice. Arch. Biochem. Biophys. 2003, 409: 153-158.
81. Thummel, K.E., Wilkinson, G.R. In vitro and in vivo drug interactions involving human CYP3A. Annu. Rev. Pharmacol. Toxicol. 1998, 38: 389-430.
82. Evans, W.E., Relling, M.V. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 1999, 286: 487-491.
83. Daly, A.K. Significance of the minor cytochrome P450 3A isoforms. Clin. Pharmacokinet. 2006, 45: 13-31.
84. Domanski, T.L, Finta, C., Halpert, J.R., Zaphiropoulos, P.G. cDNA cloning and initial characterization of CYP3A43, a novel human cytochrome P450. Mol. Pharmacol. 2001, 59: 386-392.
85. Koch, I., Weil, R., Wolbold, R., Brockmöller, J., Hustert, E., Burk, O., Nuessler, A., Neuhaus, P., Eichelbaum, M., Zanger, U., Wojnowski, L. Interindividual variability and tissue-specificity in the expression of cytochrome P450 3A mRNA. Drug Metab. Dispo. 2002, 30: 1109-1114.
86. Westlind. A., Malmebo, S., Johansson, I., Otter, C., Andersson, T.B., Ingelman-Sundberg, M., Oscarson, M. Cloning and tissue distribution of a novel human cytochrome p450 of the CYP3A sub-family, CYP3A43. Biochem. Biophys. Res. Commun. 2001, 281: 1349-1355.
87. Gellner, K., Eiselt, R., Hustert, E., Arnold, H., Koch, I., Haberl, M., Deglmann, C.J., Burk, O., Buntefuss, D., Escher, S., Bishop, C., Koebe, H.G., Brinkmann, U., Klenk, H.P., Kleine, K., Meyer, U.A., Wojnowski, L. Genomic organization of the human CYP3A locus: identification of a new, inducible CYP3A gene. Pharmacogenetics 2001, 11: 111-121.
88. Krusekopf, S., Roots, I., Kleeberg, U. Differential drug-induced mRNA expression of human CYP3A4 compared to CYP3A5, CYP3A7 and CYP3A43. Eur. J. Pharmacol. 2003, 466: 7-12.
89. Finta, C., Zaphiropoulos, P.G. Intergenic mRNA molecules resulting from trans-splicing. J. Biol. Chem. 2002, 277: 5882-5890.
90. Cauffiez. C., Lo-Guidice, J.M., Chevalier, D., Allorge, D., Hamdan, R., Lhermitte, M., Lafitte, J.J., Colombel, J.F., Libersa, C., Broly, F. First report of a genetic polymorphism of the cytochrome P450 3A43 (CYP3A43) gene: identification of a loss-of-function variant. Hum. Mutat. 2004, 23: 101.
91. Stone, A., Ratnasinghe, L.D., Emerson, G.L., Modali, R., Lehman, T., Runnells, G., Carroll, A., Carter, W., Barnhart, S., Rasheed, A.A., Greene, G., Johnson, D.E., Ambrosone, C.B., Kadlubar, F.F., Lang, NP. CYP3A43 Pro(340)Ala polymorphism and prostate cancer risk in African Americans and Caucasians. Cancer Epidemiol. Biomarkers Prev. 2005, 14: 1257-1261.
92. Zeigler-Johnson, C., Friebel, T., Walker, A.H., Wang, Y., Spangler, E., Panossian, S., Patacsil, M., Aplenc, R., Wein, A.J., Malkowicz, S.B., Rebbeck, T.R. CYP3A4, CYP3A5, and CYP3A43 genotypes and haplotypes in the etiology and severity of prostate cancer. Cancer Res. 2004, 64: 8461-8467.
93. Fleming, I. Cytochrome P-450 under pressure: more evidence for a link between 20-hydroxyeicosatetraenoic acid and hypertension. Circulation 2005, 111: 5-7.
94. Bellamine, A., Wang, Y., Waterman, M.R., Gainer, J.V. 3rd, Dawson, E.P., Brown, N.J., Capdevila, J.H. Characterization of the CYP4A11 gene, a second CYP4A gene in humans. Arch. Biochem. Biophys. 2003, 409: 221-227.
95. Savas, U., Hsu, M.H., Johnson, E.F. Differential regulation of human CYP4A genes by peroxisome proliferators and dexamethasone. Arch. Biochem. Biophys. 2003, 409: 212-220.
96. Gainer, J.V., Bellamine, A., Dawson, E.P., Womble, K.E., Grant, S.W., Wang, Y., Cupples, L.A., Guo, C.Y., Demissie, S., O'Donnell, C.J., Brown, N.J., Waterman, M.R., Capdevila, J.H. Functional variant of CYP4A11 20-hydroxyeicosatetraenoic acid synthase is associated with essential hypertension. Circulation 2005, 111: 63-69.
97. Hiratsuka, M., Nozawa, H., Katsumoto, Y., Moteki, T., Sasaki, T., Konno, Y., Mizugaki, M. Genetic polymorphisms and haplotype structures of the CYP4A22 gene in a Japanese population. Mutat. Res. 2006 [Epub ahead of print].
98. Burk, O., Wojnowski, L. Cytochrome P450 3A and their regulation. Naunyn Schmiedebergs Arch Pharmacol. 2004, 369: 105-124.
99. Ingelman-Sundberg, M., Oscarson, M., McLellan, R.A. Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment. Trends Pharmacol. Sci. 1999, 20: 342-349.
100. Hedlund, E., Gustafsson, J.A., Warner, M. Cytochrome P450 in the brain; a review. Curr. Drug Metab. 2001, 2: 245-263.
101. Kivisto, K.T., Kroemer, H.K., Eichelbaum, M. The role of human cytochrome P450 enzymes in the metabolism of anticancer agents: implications for drug interactions. Br. J. Clin. Pharmacol. 1995, 40: 523-530.
102. Choudhary, D., Jansson, I., Stoilov, I., Sarfarazi, M., Schenkman, J.B. Expression patterns of mouse and human CYP orthologs (families 1-4) during development and in different adult tissues. Arch. Biochem. Biophys. 2005, 436: 50-61.
103. Domanski; T.L., Halpert, J.R. Analysis of mammalian cytochrome P450 structure and function by site-directed mutagenesis. Curr. Drug Metab. 2001, 2: 117-137.
104. Robertson, G.R., Field, J., Goodwin, B., Bierach, S., Tran, M., Lehnert, A., Liddle, C. Transgenic mouse models of human CYP3A4 gene regulation. Mol. Pharmacol. 2003, 64: 42-50.